CCO Independent Conference Coverage of the 2005 American Association for the Study of Liver Diseases Annual Meeting* November 11-15, 2005 - San Francisco, CA

*CCO is an independent medical education company that provides state-of-the-art medical information

to healthcare professionals through conference coverage and other educational programs.

HCV Management: Facing New Challenges

High-Dose Ribavirin plus Peginterferon With Epoetin Alfa Leads to Higher Sustained Virologic Response for HCV Genotype 1

Shorter Treatment With Peginterferon Alfa-2a Plus Ribavirin Possible In HCV Genotype 1 'Super-Responders'?

Some HCV-Infected Interferon Nonresponders/ Relapsers Achieve Sustained Virologic Response Following 48-Week Retreatment With Peginterferon Alfa-2b Plus Ribavirin

SCH 503034 Demonstrated Potent Activity in Genotype 1 HCV Patients Previously Failing Peginterferon

etc...

Full program on

http://clinicaloptions.com/Hepatitis/Conference Coverage/San Francisco 2005.aspx